Advanced Biomed Inc.
ADVBNasdaq
$5.03
↑ +2.7%Jul 17 close · end-of-day
Price
1Y↓ -68.0%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$6.5M
Enterprise Value
$6.5M
P/E
4.3
P/S
—
P/B
0.7
EV/EBITDA
—
PEG
—
FCF Yield
-45.6%
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
$5.3M
Free Cash Flow (TTM)
-$2.9M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
57.3%
ROIC
—
Debt / Equity
—
Net Cash
—
Return 1Y
-65.9%
Company profile
Our Mission We are committed to the application research of integrating semiconductor technology and biotechnology. Our principal executive offices are located at No. 689-85, Xiaodong Rd., Yongkang Dist., Tainan City 710, Taiwan.
- CEO
- Yi Lu
- Sector
- Services
- Industry
- Healthcare
- Employees
- 40
- Headquarters
- Nevada
- Website
- www.advanbiomed.com/
Earnings
ADVB Q3 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.38↓ -71.9%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2024 | FY2025 |
|---|---|---|
| Revenue | — | — |
| Gross profit | — | — |
| Operating income | — | — |
| Net income | -$2.8M | -$3.3M |
| Diluted EPS | -$0.14 | -$0.16 |
| Operating cash flow | -$2.1M | -$5.8M |
| Free cash flow | -$2.2M | -$5.9M |
| Gross margin | — | — |
| Operating margin | — | — |
| Net margin | — | — |
| Line item | Q3 '24 | Q1 '24 | Q2 '24 | Q3 '25 | Q4 '25 | Q1 '25 | Q2 '25 | Q3 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | — | — | — | — | — | — | — | — |
| Net income | -$1.1M | -$265,580.00 | -$907,904.00 | -$1.4M | -$701,611.00 | -$386,901.00 | $6.9M | -$488,942.00 |
| Diluted EPS | -$0.05 | -$0.01 | -$0.05 | -$1.35 | $1.25 | -$0.02 | $0.31 | -$0.38 |
| Operating cash flow | -$1.1M | -$29,680.00 | -$841,841.00 | -$3.4M | -$1.5M | -$610,342.00 | -$513,558.00 | -$239,775.00 |
| Free cash flow | -$1.1M | -$49,658.00 | -$852,533.00 | -$3.4M | -$1.6M | -$612,113.00 | -$526,464.00 | -$241,039.00 |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Dec 30, 2025
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.